Role of isocitrate dehydrogenase 1/2 (IDH 1/2) gene mutations in human tumors

Area of Science:

• Biochemistry and Molecular Biology
• Oncology
• Genetics

Background:

• Frequent isocitrate dehydrogenase 1/2 (IDH1/IDH2) gene mutations are observed across various tumor types.
• These mutations alter arginine residues in the catalytic active site, conferring a novel enzymatic function.
• The mutated enzymes catalyze alpha-ketoglutarate (α-KG) to R-2-hydroxyglutarate (2-HG).

Purpose of the Study:

• To review current research on isocitrate dehydrogenase 1/2 (IDH1/IDH2) mutations.
• To elucidate the mechanisms by which IDH1/IDH2 mutations contribute to tumorigenesis.
• To examine the clinical characteristics associated with IDH1/IDH2 mutations in tumors.

Main Methods:

• Literature review of studies on IDH1/IDH2 mutations.
• Analysis of enzymatic alterations and metabolite production (2-HG).
• Correlation of mutation status with tumor progression and prognosis.

Main Results:

• Mutated IDH1/IDH2 enzymes produce 2-HG, which competitively inhibits α-KG-dependent enzymes.
• This inhibition by 2-HG is implicated in the process of tumorigenesis.
• IDH1/IDH2 mutation status is significantly related to the progression and prognosis of specific cancers.

Conclusions:

• IDH1/IDH2 mutations represent a critical mechanism in cancer development.
• The oncometabolite 2-HG plays a key role in IDH1/IDH2-driven tumorigenesis.
• IDH1/IDH2 mutations are promising biomarkers for early cancer diagnosis, prognosis, and targeted therapeutic strategies.